At a Glance
- Company: AsymBio (Asymchem Group subsidiary)
- Location: Global operations; China bases
- Main headline: Supported 70+ INDs, 13 NDAs
- Focus area: ADCs, NDCs, antibodies, recombinant proteins
- Next steps: Expand beyond ADCs into NDCs
What happened?
AsymBio announced integrated technology platforms covering the full biopharmaceutical lifecycle from early development to commercial manufacturing. The CDMO supports ADCs, novel drug conjugates (NDCs), antibodies and recombinant proteins via cell line development, process optimisation, conjugation, drug product and analytical services.
Why does it matter?
AsymBio’s platforms enable rapid timelines (upstream processes in 9 weeks) and complex modalities like dual-payload ADCs, peptide-drug conjugates and multispecifics. The Conjugation Toolbox, shortlisted for World ADC Awards, supports cysteine/lysine/enzymatic conjugation methods.
Who’s behind it?
AsymBio leverages Asymchem’s 25+ years of manufacturing experience with AmigoCHO™ cell lines, IMPACT drug product platform and payload-linker expertise (Auristatin, PBD dimer, macrocyclic glues).
How was it achieved?
End-to-end workflows integrate AmigoCHO™ development, upstream/downstream processing, modular conjugation, high-concentration formulations and CQAs characterisation across preclinical to commercial stages.
What’s next?
Continued R&D investment to accelerate innovative therapies; expansion into NDCs while maintaining ADC/antibody leadership.
What are people saying? (optional)
AsymBio: “Technology-driven CDMO… accelerating innovation through integrated services.”